Established a new share issuance shelf of 50 million USD as a U.S. ATM Offering. Sales agent: Lucid Capital Markets; fee: 3.0% of gross proceeds. Offerings targeted to the U.S. market, from 2025-12-29 until the shelf limit is reached. Proceeds intended to fund R&D for MN-166 and MN-001 and general corporate purposes. Announced correction of disclosure delays and strengthening of internal controls.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4875","jir_company_name":"MediciNova, Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-21","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4875-20261021-01.pdf","jir_short_summary":"Established a new share issuance shelf of 50 million USD as a U.S. ATM Offering. Sales agent: Lucid Capital Markets; fee: 3.0% of gross proceeds. Offerings targeted to the U.S. market, from 2025-12-29 until the shelf limit is reached. Proceeds intended to fund R&D for MN-166 and MN-001 and general corporate purposes. Announced correction of disclosure delays and strengthening of internal controls.","jir_summary":"### Key Points\nMediciNova, Inc. has established a shelf for new share issuance in the United States and entered into a sales agency agreement enabling ATM-style fundraising. The shelf is for 50 million USD, the sales agent is Lucid Capital Markets, the fee is 3.0% of gross proceeds, offerings are targeted to the U.S. market, and proceeds are intended to be applied to the research and development of MN-166 and MN-001 and to general corporate expenses.\n\n### Future Impact and Risk Factors\nThe company has announced correction of delayed timely disclosures and strengthening of internal controls. While this secures a flexible fundraising tool, note that no public offering or secondary offering will be conducted in the Japanese market. The timing and market conditions for any issuance may be affected by future clinical trial and development funding needs and market trends.","jir_financial_highlights":"Type of Securities: Common stock (Unknown)\nShelf Amount: 50 million USD (Unknown)\nSales Agent: Lucid Capital Markets, LLC (Unknown)\nOffering Period: From 2025-12-29 until the shelf limit is reached (Unknown)\nUse of Proceeds: To be applied to research and development of MN-166 and MN-001 and for general corporate purposes (Unknown)","jir_category":"","jir_hashtags":"#MediciNova, #CapitalPolicyRelated, #ATMOffering","jir_key_figures":"Shelf Amount: 50 million USD\nOffering Region: United States\nFee: 3.0% of gross proceeds","jir_meta_title":"MediciNova, Inc. Establishes U.S. ATM Offering Shelf for New Share Issuance | October 2026","jir_meta_description":"MediciNova, Inc. has established a 50 million USD new share issuance shelf in the U.S. and entered into a sales agency agreement. Proceeds are intended to fund R&D for MN-166 and MN-001; the company also announced corrections to disclosure delays and strengthened internal controls.","jir_og_title":"MediciNova, Inc. Establishes U.S. ATM Offering Shelf for New Share Issuance","jir_og_description":"Announced establishment of a new share issuance shelf for the U.S. market, the fundraising purpose for MN-166 and MN-001, and an overview of the sales agency agreement. The company also announced correction of disclosure delays.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58821,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-133128","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n